Nebraska is currently home to 711 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Omaha, Lincoln, Kearney and Grand Island. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
NCT05781399
Recruiting
The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailability between a tablet and suspension formulation of JNT-517 and the food effect in healthy volunteers. All participants in Part C will receive JNT-517. The goal of Part D is to assess the safety, tolera... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/27/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Phenylketonuria
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/26/2024
Locations: Clinical Site, Lincoln, Nebraska
Conditions: Bipolar Depression
Register for Updates
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT05069038
Recruiting
Patients with estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) breast cancer do not achieve good responses with pre-operative chemotherapy. The sensitivity of breast cancer to chemotherapy is often determined by the underlying gene expression pattern and the molecular subtype of the tumor. In addition, not all patients tolerate chemotherapy well. Pre-operative endocrine therapy has emerged as an effective strategy to improve outcomes in patients with early-stage hormo... Read More
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
07/26/2024
Locations: Unversity of Nebraska Medical Center, Omaha, Nebraska
Conditions: Breast Cancer
Register for Updates
Association of Periodontal Inflammation on Immune Response in Wound Healing
NCT04805320
Recruiting
Subjects who are in need of extraction of a posterior tooth will be recruited for this study. Prior to extraction, periodontal clinical markers of inflammation, body-mass index and dental radiographs will be measured/taken. The posterior tooth will be atraumatically extracted and a small soft tissue biopsy of the extraction site will be taken. At the two week follow-up, sutures will be removed and another small biopsy of soft tissue will be taken. Subjects will be seen again at 3 months for a fi... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
07/26/2024
Locations: University of Nebraska, College of Dentistry, Lincoln, Nebraska
Conditions: Inflammation of Mouth
Register for Updates
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
NCT04799470
Recruiting
This is an open-label, non-randomized, proof-of-concept comparison of clinical vs. research stimulation patterns in patients with Parkinson's disease (PD) being treated with Deep Brain Stimulation (DBS) through the Medtronic Percept PC DBS device. The investigators hypothesize that stimulation patterns designed to better target excessive synchrony in a patient-tailored manner may result in more efficient and effective therapy with fewer side effects. Medtronic 3rd-generation sensing implantable... Read More
Gender:
ALL
Ages:
Between 19 years and 80 years
Trial Updated:
07/26/2024
Locations: Unversity of Nebraska Medical Center, Omaha, Nebraska
Conditions: Parkinson's Disease
Register for Updates
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
NCT05950334
Recruiting
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Relapsed/Refractory B-Cell Lymphoma
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Ulcerative Colitis
Register for Updates
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2024
Locations: Sensation-NOW: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Peripheral Nerve Injuries
Register for Updates
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04278768
Recruiting
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Register for Updates
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
NCT04248283
Recruiting
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
Gender:
FEMALE
Ages:
22 years and above
Trial Updated:
07/22/2024
Locations: CHI Health Research Center, Omaha, Nebraska
Conditions: Urinary Incontinence, Urinary Incontinence,Stress
Register for Updates
Beacon Sensors and Telerehabilitation to Assess and Improve Use of Devices (BeST-AID) for Low Vision
NCT06107881
Recruiting
One goal of this research is to conduct a non-inferiority trial of telerehabilitation versus in-office care to provide follow-up training to individuals with low vision to enhance their quality of life by using magnification devices and/or visual assistive mobile apps for important daily activities, such as reading and/or other valued tasks. This is a high priority given the increasing prevalence of low vision, paucity of low vision rehabilitation providers, and barriers related to access to car... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: University of Nebraska: Weigel Williamson Center for Visual Rehabilitation at the Truhlsen Eye Institute, Omaha, Nebraska
Conditions: Low Vision, Low Vision Aids
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates